This is a mechanistic, observational, prospective, case and control study, to compare platelet aggregation, analyzed by Multiplate-ADP, in hospitalized patients diagnosed with COVID-19 versus healthy controls. Thus will be included 60 patients who present with respiratory symptoms within 72 hours of hospitalization and confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive serology for SARS-CoV-2 - COVID group); this group will be compared to 60 healthy individuals (asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous group.
There is strong evidence that SARS-CoV-2 infection is associated with atherothrombotic
phenomena. However, platelet activity in COVID-19 has not yet been studied.
Thus, the main objective of this project is to evaluate platelet aggregation by the
Multiplate-ADP method in hospitalized patients diagnosed with COVID-19, in comparison with
the platelet aggregation evaluated by the same method in healthy controls.
Secondary objectives include the assessment of parameters related to coagulation,
inflammation, and clinical outcome variables.
This is a mechanistic, observational, prospective, case and control study, which will include
60 patients who present with respiratory symptoms within 72 hours of hospitalization and
confirmation of the diagnosis of COVID-19 by laboratory method (RT -PCR and / or positive
serology for SARS-CoV-2 - COVID group); this group will be compared to 60 healthy individuals
(asymptomatic and with negative SARS-CoV-2 serology), matched by sex and age to the previous
group.
Other: venipuncture in peripheral vein
single vacuum venipuncture in peripheral vein
Inclusion Criteria:
- Agreement to sign the Free and Informed Consent Form (ICF).
- Case group: patients with up to 72 hours of hospitalization for respiratory symptoms.
- Control group: healthy volunteers, defined as having no history (confirmed or
suspected) of COVID-19 or chronic diseases (except hypertension, obesity,
dyslipidemia)
Exclusion Criteria:
- Known platelet dysfunction or platelet count <100,000 / µL or> 450,000 / µL;
- Terminal illness;
- Known liver disease or clotting disorder;
- Hematocrit less than 34% or greater than 55%;
- Previous use of antiplatelet agents and / or anticoagulants (except acetylsalicylic
acid and prophylactic heparin);
- Patients on invasive mechanical ventilation or receiving high oxygen flow.
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
Sao Paulo, Brazil
Instituto de infectologia Emílio Ribas
São Paulo, Brazil